药物性肝衰竭的临床特点及诊治策略

赖荣陶; 谢青

doi:10.3969/j.issn.1001-5256.2021.11.006

药物性肝衰竭的临床特点及诊治策略

DOI: 10.3969/j.issn.1001-5256.2021.11.006

赖荣陶,
谢青^,

上海交通大学医学院附属瑞金医院感染科，上海 200025

基金项目:

国家自然科学基金项目 (82070604);

国家自然科学基金项目 (81770587);

国家自然科学基金项目 (81970514);

上海市卫生健康委员会科研面上项目 (202040111);

上海市临床重点专科(感染病学) (shslczdzk01103);

十三五“科技部重大专项” (2017ZX10203201-008);

十三五“科技部重大专项” (2018ZX09201016-003-001);

十三五“科技部重大专项” (2017ZX10202202-005-004)

详细信息

通信作者:
谢青，xieqingrjh@163.com

中图分类号: R575
计量
- 文章访问数: 521
- HTML全文浏览量: 115
- PDF下载量: 226
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-15
- 录用日期: 2021-09-15
- 出版日期: 2021-11-20

Clinical features of drug-induced liver failure and related diagnosis and treatment strategies

Rongtao LAI,
Qing XIE^,

Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Research funding:

National Natural Science Foundation of China (82070604);

National Natural Science Foundation of China (81770587);

National Natural Science Foundation of China (81970514);

Shanghai Municipal Planning Commission of science and Research Fund (202040111);

Shanghai Municipal Key Clinical Specialty (shslczdzk01103);

Major Projects of the Ministry of Science and Technology during the 13th Five-Year Plan period (2017ZX10203201-008);

Major Projects of the Ministry of Science and Technology during the 13th Five-Year Plan period (2018ZX09201016-003-001);

Major Projects of the Ministry of Science and Technology during the 13th Five-Year Plan period (2017ZX10202202-005-004)

摘要

摘要: 药物性肝损伤(DILI)发生率逐年上升，其中药物相关的肝衰竭病情严重、治疗手段有限、病死率高，应引起临床医师的高度重视。对乙酰氨基酚(APAP)是西方国家急性肝衰竭(ALF)的最常见原因，除此之外，由于目前缺乏对宿主易感性和发病机制的深入了解，特异性DILI诱发的ALF患者早期不易被识别，自发恢复率低，预后更为凶险，已成为多个国家紧急肝移植的主要适应征。全面了解药物性肝衰竭的临床特征和预后，寻求新的可靠诊断方法和有效的治疗策略对降低药物相关肝衰竭的疾病负担至关重要。
- 化学性与药物性肝损伤 /
- 肝功能衰竭 /
- 诊断 /
- 治疗学
Abstract: The incidence of drug-induced liver injury (DILI) has risen considerably in recent years. Drug-induced liver failure tends to have severe conditions, limited therapeutic strategy, and a high mortality rate and should thus be taken seriously by clinicians. N-acetyl-p-aminophenol is the most common cause of acute liver failure (ALF) in Western countries; for ALF associated with idiosyncratic DILI (iDILI), since there is little in-deep understanding of host susceptibility and pathogenesis, it is difficult to identify ALF caused by iDILI in the early stage, and due to a low rate of spontaneous recovery and poor prognosis, it has become a major indication for emergency liver transplantation in many countries. A comprehensive understanding of the clinical features and prognostic prediction of drug-induced liver failure and the search for new reliable diagnostic methods and effective treatment strategies are of vital importance in reducing the disease burden of drug-induced liver failure.
- Chemical and Drug-Induced Liver Injury /
- Liver Failure /
- Diagnosis /
- Therapeutics

HTML全文

参考文献(33)

[1]	REUBEN A, TILLMAN H, FONTANA RJ, et al. Outcomes in adults with acute liver failure between 1998 and 2013: An observational cohort study[J]. Ann Intern Med, 2016, 164(11): 724-732. DOI: 10.7326/M15-2211.
[2]	REUBEN A, KOCH DG, LEE WM. Drug-induced acute liver failure: Results of a U.S. multicenter, prospective study[J]. Hepatology, 2010, 52(6): 2065-2076. DOI: 10.1002/hep.23937.
[3]	CRAIG DG, BATES CM, DAVIDSON JS, et al. Overdose pattern and outcome in paracetamol-induced acute severe hepatotoxicity[J]. Br J Clin Pharmacol, 2011, 71(2): 273-282. DOI: 10.1111/j.1365-2125.2010.03819.x.
[4]	SHEN T, LIU Y, SHANG J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241. e11. DOI: 10.1053/j.gastro.2019.02.002.
[5]	SGRO C, CLINARD F, OUAZIR K, et al. Incidence of drug-induced hepatic injuries: A French population-based study[J]. Hepatology, 2002, 36(2): 451-455. DOI: 10.1053/jhep.2002.34857.
[6]	HILLMAN L, GOTTFRIED M, WHITSETT M, et al. Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury[J]. Am J Gastroenterol, 2016, 111(7): 958-965. DOI: 10.1038/ajg.2016.114.
[7]	MURRAY KF, HADZIC N, WIRTH S, et al. Drug-related hepatotoxicity and acute liver failure[J]. J Pediatr Gastroenterol Nutr, 2008, 47(4): 395-405. DOI: 10.1097/MPG.0b013e3181709464.
[8]	TREY C, DAVIDSON CS. The management of fulminant hepatic failure[J]. Prog Liver Dis, 1970, 3: 282-298.
[9]	TANDON BN, BERNAUAU J, O'Grady J, et al. Recommendations of the International Association for the Study of the Liver Subcommittee on nomenclature of acute and subacute liver failure[J]. J Gastroenterol Hepatol, 1999, 14(5): 403-404. DOI: 10.1046/j.1440-1746.1999.01905.x.
[10]	CRAIG DG, ZAFAR S, REID TW, et al. The sequential organ failure assessment (SOFA) score is an effective triage marker following staggered paracetamol (acetaminophen) overdose[J]. Aliment Pharmacol Ther, 2012, 35(12): 1408-1415. DOI: 10.1111/j.1365-2036.2012.05102.x.
[11]	BERNAL W, AUZINGER G, DHAWAN A, et al. Acute liver failure[J]. Lancet, 2010, 376(9736): 190-201. DOI: 10.1016/S0140-6736(10)60274-7.
[12]	REDDY KR, ELLERBE C, SCHILSKY M, et al. Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States[J]. Liver Transpl, 2016, 22(4): 505-515. DOI: 10.1002/lt.24347.
[13]	ANDRADE RJ, LUCENA MI, FERNÁNDEZ MC, et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period[J]. Gastroenterology, 2005, 129(2): 512-521. DOI: 10.1016/j.gastro.2005.05.006.
[14]	BERNUAU J, BENHAMOU JP. Classifying acute liver failure[J]. Lancet, 1993, 342(8866): 252-253. DOI: 10.1016/0140-6736(93)91809-z.
[15]	RIORDAN SM, WILLIAMS R. Liver disease due to illicit substance use[J]. Addict Biol, 1998, 3(1): 47-53. DOI: 10.1080/13556219872335.
[16]	WAI CT, TAN BH, CHAN CL, et al. Drug-induced liver injury at an Asian center: A prospective study[J]. Liver Int, 2007, 27(4): 465-474. DOI: 10.1111/j.1478-3231.2007.01461.x.
[17]	SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific association for the study of the liver (APASL): An update[J]. Hepatol Int, 2019, 13(4): 353-390. DOI: 10.1007/s12072-019-09946-3.
[18]	SARIN SK, KUMAR A, ALMEIDA JA, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)[J]. Hepatol Int, 2009, 3(1): 269-282. DOI: 10.1007/s12072-008-9106-x.
[19]	DEVARBHAVI H, CHOUDHURY AK, SHARMA MK, et al. Drug-induced acute-on-chronic liver failure in Asian patients[J]. Am J Gastroenterol, 2019, 114(6): 929-937. DOI: 10.14309/ajg.0000000000000201.
[20]	HERNAEZ R, SOLÀ E, MOREAU R, et al. Acute-on-chronic liver failure: An update[J]. Gut, 2017, 66(3): 541-553. DOI: 10.1136/gutjnl-2016-312670.
[21]	TESCHKE R, SCHULZE J, EICKHOFF A, et al. Drug induced liver injury: Can biomarkers assist RUCAM in causality assessment?[J]. Int J Mol Sci, 2017, 18(4): 803. DOI: 10.3390/ijms18040803.
[22]	BENICHOU C, DANAN G, FLAHAULT A. Causality assessment of adverse reactions to drugs—Ⅱ. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge[J]. J Clin Epidemiol, 1993, 46(11): 1331-1336. DOI: 10.1016/0895-4356(93)90102-7.
[23]	KLEINER DE, CHALASANI NP, LEE WM, et al. Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations[J]. Hepatology, 2014, 59(2): 661-670. DOI: 10.1002/hep.26709.
[24]	KEAYS R, HARRISON PM, WENDON JA, et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: A prospective controlled trial[J]. BMJ, 1991, 303(6809): 1026-1029. DOI: 10.1136/bmj.303.6809.1026.
[25]	NABI T, NABI S, RAFIQ N, et al. Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: A prospective study[J]. Saudi J Gastroenterol, 2017, 23(3): 169-175. DOI: 10.4103/1319-3767.207711.
[26]	HU J, ZHANG Q, REN X, et al. Efficacy and safety of acetylcysteine in "non-acetaminophen" acute liver failure: A meta-analysis of prospective clinical trials[J]. Clin Res Hepatol Gastroenterol, 2015, 39(5): 594-599. DOI: 10.1016/j.clinre.2015.01.003.
[27]	RAKELA J, MOSLEY JW, EDWARDS VM, et al. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group[J]. Dig Dis Sci, 1991, 36(9): 1223-1228. DOI: 10.1007/BF01307513.
[28]	MINDIKOGLU AL, MAGDER LS, REGEV A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: Analysis of the United Network for Organ Sharing database[J]. Liver Transpl, 2009, 15(7): 719-729. DOI: 10.1002/lt.21692.
[29]	CHOUDHARY NS, SAIGAL S, SARAF N, et al. Good outcome of living donor liver transplantation in drug-induced acute liver failure: A single-center experience[J]. Clin Transplant, 2017, 31(3): e12907. DOI: 10.1111/ctr.12907.
[30]	LAI R, XIANG X, MO R, et al. Protective effect of Th22 cells and intrahepatic IL-22 in drug induced hepatocellular injury[J]. J Hepatol, 2015, 63(1): 148-155. DOI: 10.1016/j.jhep.2015.02.004.
[31]	MCPHAIL MJ, FARNE H, SENVAR N, et al. Ability of King's College Criteria and Model for End-Stage Liver Disease scores to predict mortality of patients with acute liver failure: A Meta-analysis[J]. Clin Gastroenterol Hepatol, 2016, 14(4): 516-525. e5; quiz e43-e45. DOI: 10.1016/j.cgh.2015.10.007.
[32]	KOCH DG, TILLMAN H, DURKALSKI V, et al. Development of a model to predict transplant-free survival of patients with acute liver failure[J]. Clin Gastroenterol Hepatol, 2016, 14(8): 1199-1206. e2. DOI: 10.1016/j.cgh.2016.03.046.
[33]	ROBLES-DIAZ M, LUCENA MI, KAPLOWITZ N, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury[J]. Gastroenterology, 2014, 147(1): 109-118. e5. DOI: 10.1053/j.gastro.2014.03.050.